Australia's CSL boosts profits 19%; Merck trains farmers amid Zilmax scare; U.K. watchdog recommends EGFR tests;

@FiercePharma: With Pfizer, Novartis out, Amgen faces 1 possible rival for Onyx, per Bloomberg: AstraZeneca. Article | Follow @FiercePharma

@EricPFierce: India's Aurobindo buys, boosts capacity in sterile injectables, a hot market. Story from FiercePharmaManufacturing.com | Follow @EricPFierce

@CarlyHFierce: Here's the release on Boehringer earnings - BI says Pradaxa, Trajenta, Spiriva driving growth. Release | Follow @CarlyHFierce

> Australia's blood-products specialist CSL posted a 19% increase in profits to $1.2 billion on $5 billion in revenue, buoyed by strong sales of its subcutaneous immunoglobin products. Report

> Merck ($MRK) rolled out a new training program for livestock farmers using its feed additive Zilmax after Tyson Foods barred cattle that fed on the drug, worried about their problems walking or moving. Report

> The National Institute for Health and Care Excellence (NICE) in the U.K. recommended tests for lung cancer patients to determine whether they carry an EGFR gene mutation. Report

> Swiss regulators approved Takeda's new schizophrenia treatment Latuda, known generically as lurasidone. Report

> Drug distributor Celesio cut its outlook for the year, citing a price war with other distributors. Report

Medical Device News

@FierceMedDev: Bard's fate hangs with jury in latest vaginal mesh lawsuit. Article | Follow @FierceMedDev

@DamianFierce: Quintiles is buying Novella with its eye on emerging biotechs. News from FierceCRO.com | Follow @DamianFierce

@MarkHFierce: For LumiQuick, is it another case of regulators trying to assert control over a surging Dx industry? Item | Follow @MarkHFierce

> How did Israel become a hotbed for medical devices? Feature

> FDA sticks 'deadly' tag on Nova's glucose test strips. Report

> Accellent grows revenue but losses widen. Story

> Myriad soars despite rise of rivals. Article

Biotech News

@FierceBiotech: FDA's former IT boss nails down industry gig. Report from FierceBiotechIT.com | Follow @FierceBiotech

@JohnCFierce: MannKind soars after inhaled Afrezza delivers positive PhIII results. Report | Follow @JohnCFierce

@RyanMFierce: Fate Therapeutics, founded by stem cell experts, targets $69 million IPO. Article | Follow @RyanMFierce

> The hottest disease field for biotech startups and M&A might surprise you. More

> Report: Novartis puts a $10B cap on acquisition targets, but steers clear of Onyx. Article

> Industry Voices: The man who cured aging? Article

Drug Delivery News

@MichaelGFierce: Virus-killing nanoviricides win orphan status for dengue fever. Story | Follow @MichaelGFierce

> Receptor-targeted antifolate drugs yield fewer side effects. More

> Bind files $80M IPO to support PhII nanotech cancer drug delivery. News

> 'Smart' DNA-based nanomeds self-assemble to release cancer drug. Story

> MannKind's inhaled insulin delivery tech passes PhIII trial. Article

> NanoMedical Systems snags $2.3M to develop drug-releasing implant. Item

And F‚Äčinally... A vaccination campaign appears to have stalled a meningitis outbreak in the gay community in New York City. Report

Suggested Articles

Novartis and Civica Rx are patterning up to shore up supply of six key generic injectables used in acute care settings in hospitals.

EU health commissioner Stella Kyriakides reportedly spoke with Gilead execs to iron out a deal to secure remdesivir supply for 16 EU countries.

Under a $1.6 billion deal with the U.S. government, Novavax has pledged to start producing 100 million doses of a COVID-19 vaccine later this year.